Multicenter randomized and double-blind controlled clinical trial of Tang Shen Ning Granules in treating diabetic kidney disease

GAO Yan-bin,ZHOU Hui,GUAN Song,ZHAO Wen-jing,LI Bu-man,CHEN Lu-yan,TIAN Ying-xin

2017-01-01

Abstract:Objective:To observe the clinical therapeutic effect and illuminate the mechanism of Tang Shen Ning Granules (TSN) on diabetic kidney disease (DKD).Methods:A multicenter,randomized double-blind and positive drug controlled clinical trial was performed in our study.A total of 250 patients,who had been diagnosed with early stage of DKD,were randomly divided into 2 groups:the normal control group (NC group) and the treatment group (TSN group).Both 2 groups were treated with dietary control and hyperglycemia control.Moreover,the patients of NC group were treated with Losartan (50rg,qd),the patients of TSN group were treated with TSN (8g,bid).The treatment was lasted for 12 weeks.The clinical symptom,UAER,eGFR,SOD and hs-CRP were observed in 2 groups.Results:The total effective rate of TSN group was 86.0％,and the NC group was 58.8％ (P＜0.05).Compared with the NC group,TSN effectively decreased the UAE and relieved the clinical signs of DKD patients (P＜0.01).Compared with the NC group,the level of serum SOD was significantly increased and the level of MDA,hsCRP was significantly decreased in the TSN group (P＜0.05).No adverse reactions and side effects were observed during the trail.Conclusion:TSN is a safe and effective drug for the treatment of early diabetic nephropathy,and its mechanism might be related to the improvement of micro inflammatory state and oxidative stress.